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Abstract—Physiologically based pharmacokinetic (PBPK) models are
mathematical models that are largely based upon the physiological characteristics
of the species and the biochemical properties of the chemical of interest. They
quantitatively describe and predict the kinetics of pollutants inside the body
and can be of major importance for risk assessment of chemicals in marine
mammals. PBPK models which consist of five compartments (liver, blubber,
kidney, brain, and the rest of the body) were made for selected polychlorinated
biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs) in order to
address the bioaccumulation of these compounds in tissues of harbour porpoises
(Phocoena phocoena). Harbour porpoises have relatively long life spans, are
common cetaceans in the North Sea, a heavily polluted area, and are known to
be very sensitive to pollution. Models developed for all compounds (some
PCBs and PBDEs) were evaluated using existing datasets from the literature
and from analyses performed by GC-MS, the latter being obtained from
stranded porpoises in the Black Sea and the North Sea over a period of 18 years
(1990–2008) to assess spatial and temporal trends in bioaccumulation of the
respective PCBs and PBDEs. We demonstrate that PBPK models are a feasible
computational approach that can be used as a non-destructive tool for predicting
the chemical pollution status of the marine mammals.
Keywords:  PBPK modeling, harbour porpoises, PCBs, PBDEs, spatial trends,
temporal trends
BACKGROUND
Physiologically based pharmacokinetic (PBPK) modeling is an in silico or
computer-based technique that allows to show the distribution and kinetics of
chemicals in the body of an organism (Andersen, 1995; Reddy et al., 2005;
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Clewell and Clewell, III, 2008). Divided into several compartments, the body
represents a mass-balanced system in which the movements of the compound
obey the biochemical properties of the compound and the physiological
characteristics of the organism of interest (Fig. 1). Usually, a PBPK model
follows on or is strongly attached to a certain exposure experiment in organisms
like rodents (Lee et al., 2002, 2007; Emond et al., 2010). Both compound-specific
and species-specific parameters are then largely deduced from the experimental
set-up.
However, this approach is not possible as in vivo exposure experiments are
undesired and prohibited in marine mammals. For decades, toxicological research
in marine mammals has focused mainly on the analyses of chemicals in tissues of
dead, stranded animals and sometimes also in blood taken from live animals (e.g.,
Law et al., 2002; Houde et al., 2006; Lebeuf et al., 2007; Weijs et al., 2009a, b).
Currently, in vitro exposure experiments in blood or liver cell lines of marine
mammals are gaining more and more attention (McKinney et al., 2006; Das et al.,
2008; Frouin et al., 2010). This has the potential to go deeper into the toxic
mechanisms of pollutants, but lacks the knowledge to put the observed effects
into a broader perspective as it focuses on one tissue only. For marine mammals,
PBPK models can be seen as a non-destructive replacement for the traditional in
vivo investigations that can combine results of recent in vitro research and on-
going biomonitoring efforts.
Fig. 1.  Conceptual diagram of the PBPK model for PCB 153 in male and female ((*) included)
harbour porpoises. Figure taken from Weijs et al. (2010).
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PBPK MODELING IN MARINE MAMMALS
In the past, several attempts were made to develop PBPK models for some
pollutants in marine mammals. PBPK models for hydrophobic contaminants
were presented by Hickie et al. (1999) and applied to the sum of PCBs in beluga
whales (Delphinapterus leucas). The same was done for PCBs in killer whales
(Orcinus orca; Hickie et al., 2007) and for individual PCB congeners in ringed
seals (Phoca hispida; Hickie et al., 2005). PBPK models have species-specific
parameters which make that models developed for one species are of limited
value to assess bioaccumulation in tissues of other species (Clewell and Clewell,
III, 2008). Thus, we have developed new models for harbour porpoises, one of the
most abundant marine mammal species in the European North Sea. Harbour
porpoises accumulate high loads of contaminants and are considered to be
sensitive to pollution because of their limited capacities for metabolic
biotransformation of some pollutants (e.g., PCBs and PBDEs) compared to other
species such as harbour seals (Weijs et al., 2009a). Linking body burdens to in
vitro toxic effects would enhance our understanding of the pollution status in
these animals and would create opportunities towards their conservation.
Therefore, assessing body burdens through PBPK modeling of some of the most
persistent PCBs (PCB 99, 101, 118, 153, 149, 170 and 180) and PBDEs (PBDE
47, 99, 100 and 153) was performed for harbour porpoises recently (Weijs et al.,
2010, 2011, 2012).
In these studies, tissues included were the blubber, brain, kidneys, muscle
and liver to cover processes such as storage, elimination through the production
of feces and urine and through metabolic biotransformation. Parameters in the
models were either taken from the literature or were fitted to the data. Datasets
used for the evaluation of the models were from harbour porpoises from the Black
Sea and the North Sea (Weijs et al., 2010, 2011, 2012). All models run over the
entire lifetime (approximately 20 years) of the harbour porpoises.
RESULTS AND APPLICATIONS OF PBPK MODELS IN HARBOUR PORPOISES
Results reveal that the highest and lowest concentrations of the selected
PCBs and PBDEs were consistently found in the blubber and brain, respectively.
All models show that there is a huge peak in the concentrations of PCBs and
PBDEs for animals from birth until the age of 1 year mostly because of the high
concentrations of these congeners in milk (Weijs et al., 2010, 2011, 2012). After
that, concentrations decrease until the age of 3 or 4 years followed by an increase
in levels of all modeled congeners until the end of their lives. For some congeners
(e.g., PCB 101, PBDE 47), the maximum levels observed overall are the
concentrations in calves at the end of lactation. Other congeners reach a maximum
in animals at the age of 20 years (e.g., PCB 99, PCB 149, PCB 170, PCB 180,
PBDE 99, PBDE 100, PBDE 153) thereby even exceeding the peak concentrations
in calves. Reverse dosimetry modeling, thus reconstructing exposure scenarios
from a given concentration in the tissues, was also applied using data of PCBs and
PBDEs in blubber of North Sea harbour porpoises from 1990–2008. During this
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time period of 18 years, all concentrations of PCBs and PBDEs decreased,
although not at the same rate. For PBDEs, levels of PBDE 99 and PBDE 100
seemed to decrease the fastest and slowest, respectively (Weijs et al., 2012). For
PCBs, levels of PCB 101 and PCB 149 decreased the fastest and slowest,
respectively (Weijs et al., 2011). Levels of PCBs in harbour porpoises in 2008
were on average 2.8 times lower than in animals from 1990, whereas PBDEs were
on average 2.6 times lower in 2008 compared to 1990. Overall, decreases are
going slowly, thereby leaving the harbour porpoises at risk for several years to
come.
POTENTIAL APPLICATIONS OF PBPK MODELS
IN MARINE MAMMAL TOXICOLOGY
In the pharmaceutical industry, PBPK models are often used to predict and
evaluate the PK characteristics of candidate drugs, to understand and compare the
fate and disposition of chemicals in animals and humans, to help with the design
and the interpretation of toxicological studies, to calculate exposure based safety
margins and to compare the bioavailability for different dosage schemes or
administration routes (Andersen, 2003; Theil et al., 2003; Khalil and Läer, 2011;
Rowland et al., 2011). This particular industry mainly uses typical model
organisms such as rodents or rabbits for these applications and can thus control
several parameters (e.g., dosage schemes, acute versus chronic exposure) in the
experiments. It is not possible to control exposure conditions for wild marine
mammals. Nevertheless, some of the applications may still be a possibility in
marine mammal toxicology. A better understanding of the fate, kinetics and
disposition of pollutants like PCBs and PBDEs has been achieved using PBPK
models for harbour porpoises (Weijs et al., 2010, 2011) and other marine
mammal species (Hickie et al., 1999, 2005, 2007). Together with in vitro toxicity
data, these models could be useful to set up safety margins which may consequently
be a useful tool for the conservation of a species. Following the example of
Verwei et al. (2006), a combination of in vitro and in silico techniques has already
been proven to work for the prediction of in vivo embryotoxic effect levels.
Currently, on-going research is focusing on the extrapolation of the PBPK
models for several PCBs and PBDEs to other new lipophilic compounds with
similar properties. This aspect of modeling has been tested already by Wang et al.
(2000) for dioxins and deserves further attention as it would give the opportunity
to deduce the potential for bioaccumulation of an unknown compound in an
organism based on previous knowledge of the behavior of similar-looking
compounds. However, more information about the bioaccumulation processes of
these compounds in mammals is needed before such extrapolations are possible.
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